2
Clinical Trials associated with Alloreactive NK cell therapy(Green Cross Corporation)Evaluating the safety and efficacy of allogeneic NK cells on COVID-19 induced pneumonia, double blind, randomized clinical trial
Start Date27 Apr 2020 |
Sponsor / Collaborator- |
A Phase I Study of Allogeneic NK Cell Therapy in Patients With Refractory/Relapsed Lymphoma or Solid Tumor
Allogeneic natural killer (NK) cells (MG4101) were manufactured from normal healthy donor who underwent leukapheresis. These cells were processed based on a novel method for ex vivo activation and expansion using an irradiated and activated autologous feeder cell system. MG4101 has anti-tumor activities against various tumors including malignant lymphomas in vitro as well as in vivo tumor model.
100 Clinical Results associated with Alloreactive NK cell therapy(Green Cross Corporation)
100 Translational Medicine associated with Alloreactive NK cell therapy(Green Cross Corporation)
100 Patents (Medical) associated with Alloreactive NK cell therapy(Green Cross Corporation)
100 Deals associated with Alloreactive NK cell therapy(Green Cross Corporation)